Engaging In Options Activity, Cornelius P. McCarthy III Exercises Options Valued At $740K In Medpace Hldgs

Highlighted on July 24, it was unveiled in an SEC filing that III, Director at Medpace Hldgs (NASDAQ:MEDP), executed a significant transaction involving the exercise of company stock options.

What Happened: Disclosed in a Form 4 filing on Thursday with the U.S. Securities and Exchange Commission, III, Director at Medpace Hldgs, executed a strategic derivative sale. This involved exercising stock options for 1,972 shares of MEDP, resulting in a transaction value of $740,111.

As of Friday morning, Medpace Hldgs shares are down by 5.57%, with a current price of $430.3. This implies that III's 1,972 shares have a value of $740,111.

Delving into Medpace Hldgs's Background

Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

Unraveling the Financial Story of Medpace Hldgs

Revenue Growth: Medpace Hldgs's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2025, the company achieved a revenue growth rate of approximately 14.24%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Profitability Metrics: Unlocking Value

• Gross Margin: The company shows a low gross margin of 29.84%, suggesting potential challenges in cost control and profitability compared to its peers.

• Earnings per Share (EPS): Medpace Hldgs's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 3.16.

Debt Management: Medpace Hldgs's debt-to-equity ratio is below the industry average. With a ratio of 0.72, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

In-Depth Valuation Examination:

• Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 33.85, the stock indicates an attractive valuation, potentially presenting a buying opportunity.

• Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 6.34 suggests overvaluation in the eyes of investors, considering sales performance.

• EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): Medpace Hldgs's EV/EBITDA ratio of 25.43 exceeds industry averages, indicating a premium valuation in the market

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.

Delving Into the Significance of Insider Transactions

Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.

When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.

A new purchase by a company insider is a indication that they anticipate the stock will rise.

On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.

Unlocking the Meaning of Transaction Codes

When dissecting transactions, the focal point for investors is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.

Check Out The Full List Of Medpace Hldgs's Insider Trades.

Insider Buying Alert: Profit from C-Suite Moves

Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. Click here for access.

This article was generated by Benzinga's automated content engine and reviewed by an editor.